Literature DB >> 16596298

Relation of anthropometric measurements to ovarian cancer risk in a population-based case-control study (United States).

Neeraja B Peterson1, Amy Trentham-Dietz, Polly A Newcomb, Zhi Chen, Tebeb Gebretsadik, John M Hampton, Meir J Stampfer, Walter C Willett, Kathleen M Egan.   

Abstract

OBJECTIVE: To examine the relationship between anthropometric measures and ovarian cancer by menopausal status.
METHODS: We analyzed data from a population-based case-control study comprised of 700 incident cases of epithelial ovarian cancer and 5,943 population controls from Massachusetts and Wisconsin enrolled between 1993 and 2001. In a telephone interview, information was gathered on established ovarian cancer risk factors, as well as adult height and age-specific body weight. Logistic regression was used to estimate multivariate-adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for body mass index (BMI) throughout life.
RESULTS: Recent BMI had no significant association with ovarian cancer risk (P-trend 0.14 for continuous BMI), after adjustment for age and other ovarian cancer risk factors. However, a non-significant positive association (overall P-trend 0.08) was observed for BMI at age 20; the risk estimate comparing a body mass of >25 kg/m2 to the lowest quintile (<or=18.88 kg/m2) was moderately but non-significantly elevated (OR 1.46; 95% CI 0.92, 2.31).
CONCLUSION: Results of this study suggest that maintenance of a lean body mass, particularly in early adult life, may decrease ovarian cancer risk.

Entities:  

Mesh:

Year:  2006        PMID: 16596298     DOI: 10.1007/s10552-005-0416-1

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  7 in total

1.  Body size and the risk of ovarian cancer by hormone therapy use in the California Teachers Study cohort.

Authors:  Alison J Canchola; Ellen T Chang; Leslie Bernstein; Joan A Largent; Peggy Reynolds; Dennis Deapen; Katherine D Henderson; Giske Ursin; Pamela L Horn-Ross
Journal:  Cancer Causes Control       Date:  2010-10-06       Impact factor: 2.506

Review 2.  Height, body mass index, and ovarian cancer: a pooled analysis of 12 cohort studies.

Authors:  Leo J Schouten; Christine Rivera; David J Hunter; Donna Spiegelman; Hans-Olov Adami; Alan Arslan; W Lawrence Beeson; Piet A van den Brandt; Julie E Buring; Aaron R Folsom; Gary E Fraser; Jo L Freudenheim; R Alexandra Goldbohm; Susan E Hankinson; James V Lacey; Michael Leitzmann; Annekatrin Lukanova; James R Marshall; Anthony B Miller; Alpa V Patel; Carmen Rodriguez; Thomas E Rohan; Julie A Ross; Alicja Wolk; Shumin M Zhang; Stephanie A Smith-Warner
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-04-01       Impact factor: 4.254

3.  Body mass index and risk of ovarian cancer.

Authors:  Michael F Leitzmann; Corinna Koebnick; Kim N Danforth; Louise A Brinton; Steven C Moore; Albert R Hollenbeck; Arthur Schatzkin; James V Lacey
Journal:  Cancer       Date:  2009-02-15       Impact factor: 6.860

4.  Anthropometric measures and risk of epithelial ovarian cancer: results from the nurses' health study.

Authors:  Joanne Kotsopoulos; Heather J Baer; Shelley S Tworoger
Journal:  Obesity (Silver Spring)       Date:  2009-12-24       Impact factor: 5.002

Review 5.  Ovarian cancer and smoking: individual participant meta-analysis including 28,114 women with ovarian cancer from 51 epidemiological studies.

Authors:  V Beral; K Gaitskell; C Hermon; K Moser; G Reeves; R Peto
Journal:  Lancet Oncol       Date:  2012-08-03       Impact factor: 41.316

6.  Ovarian cancer and body size: individual participant meta-analysis including 25,157 women with ovarian cancer from 47 epidemiological studies.

Authors: 
Journal:  PLoS Med       Date:  2012-04-03       Impact factor: 11.069

7.  Inverse association of NSAID use and ovarian cancer in relation to oral contraceptive use and parity.

Authors:  K J Wernli; P A Newcomb; J M Hampton; A Trentham-Dietz; K M Egan
Journal:  Br J Cancer       Date:  2008-05-27       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.